We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$25.7M
AUM Growth
-$15.6M
Cap. Flow
-$14.8M
Cap. Flow %
-57.45%
Top 10 Hldgs %
100%
Holding
13
New
1
Increased
1
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$891K

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$7.72M
2
AMRN
Amarin Corp
AMRN
+$7.32M
3
VKTX icon
Viking Therapeutics
VKTX
+$598K
4
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$31K

Sector Composition

Rank Sector Weight
1 Healthcare 83.14%
2 Miscellaneous 16.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYME
1
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$8.02M 31.19%
2,175,000
– –
LAB icon
2
Standard BioTools
LAB
$252M
$3.88M 15.08%
450,000
– –
GSK icon
3
GSK
GSK
$101B
$3.82M 14.85%
80,000
– –
BIS icon
4
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$3.45M 13.41%
18,750
– –
AGN
5
DELISTED
Allergan plc
AGN
$2.67M 10.39%
20,000
– –
NVLN
6
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$1.55M 6.02%
1,800,000
+788,513
+78% +$891K
VKTX icon
7
CALL
Viking Therapeutics
VKTX
$3.95B
$765K 2.97%
+100,000
New +$1.2M
VKTX icon
8
Viking Therapeutics
VKTX
$3.95B
$765K 2.97%
100,000
-50,000
-33% -$598K
ATRS
9
DELISTED
Antares Pharma, Inc.
ATRS
$680K 2.64%
250,000
– –
LCI
10
CALL
DELISTED
Lannett Company, Inc.
LCI
$124K 0.48%
6,250
-6,250
-50% -$119K
AMRN
11
Amarin Corp
AMRN
$297M
– –
-22,500
Closed -$7.32M
GILD icon
12
Gilead Sciences
GILD
$184B
– –
-100,000
Closed -$7.72M
SEEL
13
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
-1
Closed -$31K

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Healthcare Value Capital held 13 positions worth $25.7M, down 38% from $41.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Healthcare Value Capital withdrew a net $14.8M in Q4 2018, closing 3 positions and reducing 2 holdings. Its most notable exit was Gilead Sciences, an estimated $7.72M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital added an estimated $891K to Novelion Therapeutics Inc. Common Shares.

  • Healthcare Value Capital added most to Novelion Therapeutics Inc. Common Shares in Q4 2018, an estimated $891K increase.
  • Healthcare Value Capital's biggest Q4 2018 reduction was Viking Therapeutics, cutting an estimated $598K.
  • Healthcare Value Capital fully exited Gilead Sciences in Q4 2018, selling an estimated $7.72M.
  • Healthcare Value Capital's ten largest holdings make up 100% of its $25.7M portfolio in Q4 2018.
  • Healthcare Value Capital opened 1 new position and closed 3 in Q4 2018.
  • Healthcare Value Capital's portfolio value fell 38% quarter-over-quarter to $25.7M.

Based on Healthcare Value Capital's 13F filing for Q4 2018, filed 13 Feb 2019.